Richard Goldberg M MD

Richard Goldberg M MD
ProfessorCollege of Medicinegoldberg.218@osu.edu
Starling Loving Hall 320 W 10th Avenue Columbus Ohio 43210
Phone:Fax:
  • Translational Therapeutics

Research Description

Dr. Goldberg's research focuses on clinical studies in patients with GI cancers (principally colorectal), translational studies with laboratory collaborators on biologic specimens from patients with cancer, development of new cancer drugs and drug combinations, and clinical trials methodology.

Current Publications

  • Lamont EB, Schilsky RL, He Y, Muss H, Cohen HJ, Hurria A, Meilleur A, Kindler HL, Venook A, Lilenbaum R, Niell H, Goldberg RM, Joffe S, for the Alliance for Clinical Trials in OncologyGeneralizability of Trial Results to Elderly Medicare Patients with Advanced Solid Tumors (Alliance 70802).J Natl Cancer Inst 107 1/1/2015
  • Venook AP, Ogino S, Giovannucci EL, Fuchs CS, Ng K, Meyerhardt JA, Chan AT, Sato K, Chan JA, Niedzwiecki D, Saltz LB, Mayer RJ, Benson AB 3rd, Schaefer PL, Whittom R, Hantel A, Goldberg RMAspirin and COX-2 Inhibitor Use in Patients With Stage III Colon Cancer.J Natl Cancer Inst 107 1/1/2015
  • Ciombor KK, Haraldsdottir S, Goldberg RMHow Can Next-Generation Sequencing (Genomics) Help Us in Treating Colorectal Cancer?Curr Colorectal Cancer Rep 10 372-379 12/1/2014
  • Lee AM, Shi Q, Pavey E, Alberts SR, Sargent DJ, Sinicrope FA, Berenberg JL, Goldberg RM, Diasio RBDPYD Variants as Predictors of 5-fluorouracil Toxicity in Adjuvant Colon Cancer Treatment (NCCTG N0147).J Natl Cancer Inst 106 12/1/2014
  • Nordlinger B, Poston GJ, Goldberg RMShould the Results of the New EPOC Trial Change Practice in the Management of Patients With Resectable Metastatic Colorectal Cancer Confined to the Liver?J Clin Oncol in press 11/17/2014
  • Falcone A, Tournigand C, Kabbinavar FF, Heinemann V, Van Cutsem E, Bokemeyer C, Buyse M, Sargent DJ, Shi Q, de Gramont A, Grothey A, Zalcberg J, Chibaudel B, Schmoll HJ, Seymour MT, Adams R, Saltz L, Goldberg RM, Punt CJ, Douillard JY, Hoff PM, Hecht JR, Hurwitz H, Díaz-Rubio E, Porschen R, Tebbutt NC, Fuchs C, Souglakos JIndividual Patient Data Analysis of Progression-Free Survival Versus Overall Survival As a First-Line End Point for Metastatic Colorectal Cancer in Modern Randomized Trials: Findings From the Analysis and Research in Cancers of the Digestive System Database.J Clin Oncol in press 11/10/2014
  • Blazer M, Wu C, Goldberg RM, Phillips G, Schmidt C, Muscarella P, Wuthrick E, Williams TM, Reardon J, Christopher Ellison E, Bloomston M, Bekaii-Saab TNeoadjuvant Modified (m) FOLFIRINOX for Locally Advanced Unresectable (LAPC) and Borderline Resectable (BRPC) Adenocarcinoma of the Pancreas.Ann Surg Oncol in press 10/31/2014
  • Sharma MR, Gray E, Goldberg RM, Sargent DJ, Karrison TGResampling the N9741 Trial to Compare Tumor Dynamic Versus Conventional End Points in Randomized Phase II Trials.J Clin Oncol in press 10/27/2014
  • Nichols SD, Albert S, Shirley L, Schmidt C, Abdel-Misih S, El-Dika S, Groce JR, Wu C, Goldberg RM, Bekaii-Saab T, Bloomston MOutcomes in Patients with Obstructive Jaundice from Metastatic Colorectal Cancer and Implications for Management.J Gastrointest Surg in press 10/10/2014
  • Ciombor KK, Wu C, Goldberg RMRecent Therapeutic Advances in the Treatment of Colorectal Cancer.Annu Rev Med in press 10/9/2014
  • Sinicrope FA, Shi Q, Smyrk TC, Thibodeau SN, Dienstmann R, Guinney J, Bot BM, Tejpar S, Delorenzi M, Goldberg RM, Mahoney M, Sargent DJ, Alberts SRMolecular Markers Identify Subtypes of Stage III Colon Cancer Associated with Patient Outcomes.Gastroenterology in press 10/8/2014
  • Lieu CH, Renfro LA, de Gramont A, Meyers JP, Maughan TS, Seymour MT, Saltz L, Goldberg RM, Sargent DJ, Eckhardt SG, Eng C, Aide et Recherche en Cancérologie Digestive FoundationAssociation of age with survival in patients with metastatic colorectal cancer: analysis from the ARCAD Clinical Trials Program.J Clin Oncol 32 2975-84 9/20/2014
  • O'Neil BH, Cainap C, Van Cutsem E, Gorbunova V, Karapetis CS, Berlin J, Goldberg RM, Qin Q, Qian J, Ricker JL, Fischer J, McKee MD, Carlson DM, Kim TWRandomized Phase II Open-Label Study of mFOLFOX6 in Combination With Linifanib or Bevacizumab for Metastatic Colorectal Cancer.Clin Colorectal Cancer 13 156-163.e2 9/1/2014
  • Shiovitz S, Bertagnolli MM, Renfro LA, Emond MJ, Maizels N, Niedzwiecki D, Goldberg RM, Saltz LB, Venook A, Warren RS, Grady WM, Alliance for Clinical Trials in Oncology, Nam E, Foster NR, Dzieciatkowski S, Luo Y, Lao VV, Monnat RJ JrCpG Island Methylator Phenotype Is Associated With Response to Adjuvant Irinotecan-Based Therapy for Stage III Colon Cancer.Gastroenterology 147 637-45 9/1/2014
  • Lieu CH, Renfro LA, de Gramont A, Meyers JP, Maughan TS, Seymour MT, Saltz L, Goldberg RM, Sargent DJ, Eckhardt SG, Eng CAssociation of Age With Survival in Patients With Metastatic Colorectal Cancer: Analysis From the ARCAD Clinical Trials Program.J Clin Oncol in press 7/7/2014
  • McRee AJ, Davies JM, Sanoff HG, Goldberg RM, Bernard S, Claire Dees E, Keller K, Ivanova A, O'Neil BHA phase I trial of everolimus in combination with 5-FU/LV, mFOLFOX6 and mFOLFOX6 plus panitumumab in patients with refractory solid tumors.Cancer Chemother Pharmacol 74 117-23 7/1/2014
  • Sinicrope FA, Goldberg RM, Limburg PJ, Thibodeau SN, Grothey A, Hubbard JM, Chan E, Nair S, Berenberg JL, McWilliams RR, Alliance for Clinical Trials in Oncology, Gonsalves WI, Mahoney MR, Sargent DJ, Nelson GD, Alberts SRPatient and Tumor Characteristics and BRAF and KRAS Mutations in Colon Cancer, NCCTG/Alliance N0147.J Natl Cancer Inst 106 7/1/2014
  • Haraldsdottir S, Hampel H, Wei L, Wu C, Frankel W, Bekaii-Saab T, de la Chapelle A, Goldberg RMProstate cancer incidence in males with Lynch syndrome.Genet Med 16 553-7 7/1/2014
  • Huang J, Nair SG, Mahoney MR, Nelson GD, Shields AF, Chan E, Goldberg RM, Gill S, Alliance for Clinical Trials in Oncology, Kahlenberg MS, Quesenberry JT, Thibodeau SN, Smyrk TC, Grothey A, Sinicrope FA, Webb TA, Farr GH Jr, Pockaj BA, Berenberg JL, Mooney M, Sargent DJ, Alberts SRComparison of FOLFIRI with or without cetuximab in patients with resected stage iii colon cancer; NCCTG (Alliance) intergroup trial N0147.Clin Colorectal Cancer 13 100-9 6/1/2014
  • Alliance for Clinical Trials in Oncology, Yoon HH, Tougeron D, Shi Q, Alberts SR, Mahoney MR, Nelson GD, Nair SG, Thibodeau SN, Goldberg RM, Sargent DJ, Sinicrope FAKRAS Codon 12 and 13 Mutations in Relation to Disease-Free Survival in BRAF-Wild-Type Stage III Colon Cancers from an Adjuvant Chemotherapy Trial (N0147 Alliance).Clin Cancer Res 20 3033-43 6/1/2014
  • Sanoff HK, Renfro LA, Poonnen P, Ambadwar P, Sargent DJ, Goldberg RM, McLeod HGermline variation in colorectal risk Loci does not influence treatment effect or survival in metastatic colorectal cancer.PLoS One 9 e94727 1/1/2014
  • Pavelitz T, Renfro L, Foster NR, Caracol A, Welsch P, Lao VV, Grady WB, Niedzwiecki D, Saltz LB, Bertagnolli MM, Goldberg RM, Rabinovitch PS, Emond M, Monnat RJ Jr, Maizels NMRE11-Deficiency Associated with Improved Long-Term Disease Free Survival and Overall Survival in a Subset of Stage III Colon Cancer Patients in Randomized CALGB 89803 Trial.PLoS One 9 e108483 1/1/2014
  • Nixon AB, Pang H, Starr MD, Friedman PN, Bertagnolli MM, Kindler HL, Goldberg RM, Venook AP, Hurwitz HI, Alliance for Clinical Trials In OncologyPrognostic and predictive blood-based biomarkers in patients with advanced pancreatic cancer: results from CALGB80303 (Alliance).Clin Cancer Res 19 6957-66 12/15/2013
  • Garrett CR, Bekaii-Saab TS, Ryan T, Fisher GA, Clive S, Kavan P, Shacham-Shmueli E, Buchbinder A, Goldberg RMRandomized phase 2 study of pegylated SN-38 (EZN-2208) or irinotecan plus cetuximab in patients with advanced colorectal cancer.Cancer 119 4223-30 12/15/2013
  • Alliance for Clinical Trials in Oncology, Ogino S, Liao X, Imamura Y, Yamauchi M, McCleary NJ, Ng K, Niedzwiecki D, Saltz LB, Mayer RJ, Whittom R, Hantel A, Benson AB 3rd, Mowat RB, Spiegelman D, Goldberg RM, Bertagnolli MM, Meyerhardt JA, Fuchs CSPredictive and prognostic analysis of PIK3CA mutation in stage III colon cancer intergroup trial.J Natl Cancer Inst 105 1789-98 12/4/2013
  • Goetz MP, McKean HA, Reid JM, Mandrekar SJ, Tan AD, Kuffel MA, Safgren SL, McGovern RM, Goldberg RM, Grothey AA, McWilliams R, Erlichman C, Ames MMUGT1A1 genotype-guided phase I study of irinotecan, oxaliplatin, and capecitabine.Invest New Drugs 31 1559-67 12/1/2013
  • Warren RS, Atreya CE, Niedzwiecki D, Weinberg VK, Donner DB, Mayer RJ, Goldberg RM, Compton CC, Zuraek MB, Ye C, Saltz LB, Bertagnolli MMAssociation of TP53 mutational status and gender with survival after adjuvant treatment for stage III colon cancer: results of CALGB 89803.Clin Cancer Res 19 5777-87 10/15/2013
  • Sinicrope FA, Mahoney MR, Smyrk TC, Thibodeau SN, Warren RS, Bertagnolli MM, Nelson GD, Goldberg RM, Sargent DJ, Alberts SRPrognostic impact of deficient DNA mismatch repair in patients with stage III colon cancer from a randomized trial of FOLFOX-based adjuvant chemotherapy.J Clin Oncol 31 3664-72 10/10/2013
  • Sanoff HK, Goldberg RMHow we treat metastatic colon cancer in older adults.J Geriatr Oncol 4 295-301 10/1/2013
  • Haraldsdottir S, Wu C, Bloomston M, Goldberg RMWhat is the optimal neo-adjuvant treatment for liver metastasis?Ther Adv Med Oncol 5 221-34 7/1/2013
  • Raftery L, Tepper JE, Goldberg RM, Blackstock AW, Aklilu M, Bernard SA, Ivanova A, Davies JM, O'Neil BHA two-cohort phase I study of weekly oxaliplatin and gemcitabine, then oxaliplatin, gemcitabine, and erlotinib during radiotherapy for unresectable pancreatic carcinoma.Am J Clin Oncol 36 250-3 6/1/2013
  • Van Loon K, Wigler D, Niedzwiecki D, Venook AP, Fuchs C, Blanke C, Saltz L, Goldberg RM, Meyerhardt JAComparison of dietary and lifestyle habits among stage III and metastatic colorectal cancer patients: findings from CALGB 89803 and CALGB 80405.Clin Colorectal Cancer 12 95-102 6/1/2013
  • Frankel W, Clark-Langone K, Millward C, Shak S, Goldberg RM, Mahmoud NN, Warren RS, Schilsky RL, Bertagnolli MM, Venook AP, Niedzwiecki D, Lopatin M, Ye X, Lee M, Friedman PNBiologic determinants of tumor recurrence in stage II colon cancer: validation study of the 12-gene recurrence score in cancer and leukemia group B (CALGB) 9581.J Clin Oncol 31 1775-81 5/10/2013
  • Sinicrope FA, Foster NR, Yothers G, Benson A, Seitz JF, Labianca R, Goldberg RM, Degramont A, O'Connell MJ, Sargent DJ, Adjuvant Colon Cancer Endpoints (ACCENT) GroupBody mass index at diagnosis and survival among colon cancer patients enrolled in clinical trials of adjuvant chemotherapy.Cancer 119 1528-36 4/15/2013
  • Wu C, Goldberg RMColorectal cancer in 2012: Revisiting landmark trials and identifying new therapies.Nat Rev Clin Oncol 10 71-2 2/1/2013
  • Grothey A, Van Cutsem E, Sobrero A, Siena S, Falcone A, Ychou M, Humblet Y, Bouché O, Mineur L, Barone C, Adenis A, Tabernero J, Yoshino T, Lenz HJ, Goldberg RM, Sargent DJ, Cihon F, Cupit L, Wagner A, Laurent D, CORRECT Study GroupRegorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial.Lancet 381 303-12 1/26/2013
  • Wu C, Goldberg RMManaging choices for older patients with colon cancer: adjuvant therapy.Am Soc Clin Oncol Educ Book 1/1/2013
  • Bekaii-Saab T, Goldberg RMFOLFIRINOX in locally advanced pancreas adenocarcinoma: back to the future?Oncologist 18 487-9 1/1/2013

The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) 460 W. 10th Avenue, Columbus, OH 43210 Phone: 1-800-293-5066 | Email: jamesline@osumc.edu